THE DEAL, AT A GLANCE
1/4 reviewedWhiteLab Genomics
WhiteLab Genomics
WhiteLab Genomics makes software that analyzes biological data to design safer gene and cell therapies.
WhiteLab Genomics raised $26M Series B, announced 2026-10-0801What it doesWhiteLab Genomics makes software that analyzes biological data to design safer gene and cell therapies.Source-grounded · automated review · Explore ↗
Checked 2026-10-08 · Review due 2026-10-15
Read supporting source ↗By leveraging our proprietary technology,…
02Who is involvedBacked by AVP, with new investors Yaday Health, Blast Club joining existing backers Omnes Capital, Debiopharm Innovation FundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedWhiteLab Genomics raised $26M Series B, announced 2026-10-08From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersWhiteLab Genomics raised a $26M Series B to advance AI-designed genomic medicines and position the company to move beyond computational discovery.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
WhiteLab Genomics · Financing Record
Explore source-linked visual explanations for WhiteLab Genomics. Unsupported claims are withheld while source review continues.
Record 13640 · Recorded date: 2026-10-08
Explore company records →